


## AN ENANTIOSPECIFIC SYNTHESIS OF THE SPIROKETAL PORTION OF AVERMECTIN B<sub>1a</sub>

Christina M. J. Fox, Roger N. Hiner, Ulhas Warriar, and James D. White\*  
Department of Chemistry, Oregon State University, Corvallis, Oregon, 97331, U.S.A.


**SUMMARY:** The acetonide of (3*S*,5*S*)-5,6-dihydroxy-3-*p*-methoxybenzyloxyhexanal, prepared from laevoglucosan, reacted with the cerium derivative of (3*S*,4*R*,5*S*)-3,5-dimethyl-4-*t*-butyldimethylsilyloxy-1-heptyne, prepared from (2*S*)-2-methylbutanol, to give a carbinol that was converted in four steps to the spiroketal segment of avermectin B<sub>1a</sub>.

The potent anthelmintic and antiparasitic activity associated with the avermectins<sup>1</sup> has elicited numerous and exceptionally diverse contributions from synthesis.<sup>2</sup> The endeavors directed toward de novo synthesis of these *Streptomyces* metabolites and the companion milbemycins has resulted in some noteworthy achievements, including a recent total synthesis of avermectin A<sub>1a</sub>.<sup>3</sup> Our plan for the synthesis of avermectin B<sub>1a</sub> envisions construction and convergence of the three subunits identified in its trisected formula (1). A route to the hexahydrobenzofuran moiety of 1 was reported in a recent Letter<sup>4</sup> and we now describe an enantiospecific synthesis of 2, representing the spiroketal component (C-16 to C-28) of avermectin B<sub>1a</sub>.<sup>5</sup>

A structural element common to certain avermectins that distinguishes them from milbemycins is a *sec*-butyl substituent at C-25. In consequence, a stereogenic carbon is present at C-26. This feature, together with the additional five stereogenic centers of the spiroketal of 1, suggested an approach in which alkylation of (2*S*)-2-methylbutanal (3) would be effected with a crotyl anion species to give an alkyne incorporating C-22 to C-28. This could then be coupled to a glucose-derived aldehyde (C-16 to C-21) and the resulting carbinol transformed to 2.<sup>6</sup>




1 (R = L-oleandrosyl-L-oleandrosyl)




2

The aldehyde **3** was obtained with no loss of optical purity<sup>7</sup> by Swern oxidation<sup>8</sup> of (2S)-2-methyl-1-butanol and was reacted with crotyl bromide in the presence of a chromium(II) reagent prepared in situ from chromium(III) chloride and lithium aluminum hydride.<sup>9</sup>



Scheme 1. Reagents and conditions: i,  $(\text{COCl})_2$ , DMSO,  $\text{Et}_3\text{N}$ ,  $-60^\circ\text{C}$  (82%); ii,  $\text{CrCl}_3$ ,  $\text{LiAlH}_4$ , then  $\text{CH}_3\text{CH}=\text{CHCH}_2\text{Br}$ , THF,  $25^\circ\text{C}$ ; iii,  $t\text{-BuMe}_2\text{SiOSO}_2\text{CF}_3$ , 2,6-lutidine,  $\text{CH}_2\text{Cl}_2$ ,  $0^\circ\text{C}$  (86%); iv,  $\text{O}_3$ ,  $\text{CH}_2\text{Cl}_2\text{-MeOH}$ , then  $\text{Me}_2\text{S}$ ,  $-78^\circ\text{C}$  (92%); v,  $\text{CBr}_4$ ,  $\text{PPh}_3$ , Zn dust,  $\text{CH}_2\text{Cl}_2$ ,  $25^\circ\text{C}$  (83%); vi,  $n\text{-BuLi}$  (2 equiv), THF,  $-78^\circ\text{C}$  to  $25^\circ\text{C}$ , 2 h (86%).


Diastereomeric alcohols **4**, **5**, and **6** were produced in the ratio 61:30:9 respectively, from which the desired alcohol **4** was separated chromatographically in 53% yield. This substance, after protection as its *t*-butyldimethylsilyl (TBDMS) ether, was ozonized to aldehyde **7**. The latter was converted to the substituted heptyne **9** via dibromo olefin **8** (Scheme 1).<sup>10</sup>



Scheme 2. Reagents and conditions: i, ref 9; ii,  $p\text{-TsCl}$ , pyridine- $\text{CHCl}_3$ ,  $25^\circ\text{C}$ , 50 h (90%); iii,  $\text{LiBHEt}_3$  (6 equiv), THF,  $25^\circ\text{C}$ , 48 h (55%); iv,  $\text{KH}$ ,  $p\text{-MeOC}_6\text{H}_4\text{CH}_2\text{Cl}$ , THF,  $0^\circ\text{C}$ , (80%); v,  $\text{H}_2\text{O-THF}$  (1:1),  $p\text{-TsOH}$  (cat), reflux, 5 h (78%); vi,  $\text{LiAlH}_4$ , THF,  $25^\circ\text{C}$ , 3 h, then  $\text{Me}_2\text{C(OMe)}_2$ , camphorsulfonic acid (cat),  $\text{CH}_2\text{Cl}_2$ , 1 h (56%); vii,  $(\text{COCl})_2$ , DMSO,  $\text{Et}_3\text{N}$ ,  $\text{CH}_2\text{Cl}_2$ ,  $-60^\circ\text{C}$  (82%).

The second component required for **2** was prepared from laevoglucosan (**10**), itself acquired by a known route from glucose pentaacetate.<sup>11</sup> The superfluous oxygen substituents at C-2 and C-4 were excised by reduction of ditosylate **11**<sup>12</sup> with lithium triethylborohydride, a process that led through intervening epoxides to **12** accompanied by **13** (~5:1) respectively.<sup>13</sup> Protection of **12** as its p-methoxybenzyl (MPM) ether **14**, followed by acidic hydrolysis of the anhydro bridge, yielded lactol **15**. The triol obtained upon reduction of **15** was selectively protected as its acetonide **16** and the resulting heptanol derivative was subjected to Swern oxidation to give aldehyde **17** (Scheme 2).<sup>14</sup>

Alkylation of **17** with the lithium acetylide derived from **9** gave a poor yield of **18** together with much recovered alkyne. However, the less basic alkynylcerium<sup>15</sup> reagent from **9** was more satisfactory and afforded a 67% yield of the desired alkynyl carbinol **18**. This alcohol was readily oxidized to ketone **19**. Elaboration of **19** was carried out in a straightforward sequence that entailed (i) acidic methanolysis, which removed the acetonide and led to methoxy acetal **20**, (ii) deprotection of the silyl ether to give diol **21**, and (iii) partial hydrogenation of the alkyne to cis olefin **22**, followed by a final acid-catalyzed cyclization to yield **2** (Scheme 3).<sup>6</sup> The spiroketal **2**,  $[\alpha]_D + 100.6^\circ$ , was obtained as a single stereoisomer, the structure of which was established by a detailed <sup>1</sup>H NMR study.<sup>16</sup> In particular, a n.o.e. experiment in which H-22 ( $\delta$  5.56) was irradiated resulted in a 5.5% enhancement of H-20a ( $\delta$  1.43) but no enhancement of either H-17 or H-19. This result defines the configuration of the spiro carbon unambiguously.



Scheme 3. Reagents and conditions: i, *n*-BuLi, THF,  $-78^\circ\text{C}$ , then  $\text{CeCl}_3$ , 0.5 h, then **17** (67%); ii,  $\text{MnO}_2$ ,  $\text{CH}_2\text{Cl}_2$ , 2 h (75%); iii, MeOH, camphorsulphonic acid (cat), 1 h (84%); iv,  $n\text{-Bu}_4\text{N}^+\text{F}^-$ , THF,  $50^\circ\text{C}$ , 1 h (85%); v,  $\text{H}_2$ , Pd/BaSO<sub>4</sub>, quinoline, MeOH, 0.5 h; vi, Et<sub>2</sub>O, camphorsulphonic acid, 10 min (83% from **21**).

**Acknowledgments.** We thank the Council for International Exchange of Scholars for a Fulbright grant (to C.M.J.F.) and the National Institutes of Health for financial support (grant AI10964).

## References

1. Fisher, M.H.; Mrozik, H. in 'Macrolide Antibiotics,' ed. A. Omura, Academic Press, Orlando, Florida, 1984, p. 553.
2. Hanessian, S.; Ugolini, A.; Hodges, P.J.; Beulieu, P.; Dube, D.; Andre, C. Pure Appl. Chem. **1987**, 59, 299 and references cited.
3. Danishefsky, S.J.; Armistead, D.M.; Wincott, F.E.; Selnick, H.G.; Hungate, R. J. Am. Chem. Soc., **1987**, 109, 8117.
4. White, J.D.; Dantanarayana, A.P. Tetrahedron Lett. **1987**, 28, 6417.
5. For other approaches to this system, see Barrett, A.G.M.; Raynham, T.M. Tetrahedron Lett. **1987**, 28, 5615 and references cited.
6. For a recent variation on this approach, see Baker, R.; Head, J.C.; Swain, C.J. J. Chem. Soc. Perkin Trans I **1988**, 85.
7. The optical purity of **3** can be assayed by reaction with (2R,3R)-butan-1,2-diol and examination of the resulting acetal by  $^{13}\text{C}$  NMR spectroscopy.
8. Mancuso, A.J.; Huang, S.; Swern, D. J. Org. Chem. **1978**, 43, 2480.
9. Hiyama, T.; Okude, Y.; Kimura, K.; Nozaki, H. Bull. Chem. Soc. Jpn. **1982**, 55, 561.
10. Corey, E.J.; Fuchs, P.L. Tetrahedron Lett. **1972**, 3769.
11. Coleman, G.H. Meth. Carbohydr. Chem. **1963**, 2, 394.
12. Cerny, M.; Kolvada, L.; Pacak, J. Coll. Czech. Chem. Commun. **1968**, 33, 1143.
13. Kelly, A.G.; Roberts, J.S. Carbohydr. Res. **1979**, 77, 231.
14. Horita, K.; Nagato, S.; Oikawa, Y.; Yonemitsu, O. Tetrahedron Lett. **1987**, 28, 3253.
15. Imamoto, T.; Sugiura, Y.; Takiyama, N. Tetrahedron Lett. **1984**, 25, 4233.
16.  $^1\text{H}$  NMR data for **2** (400 MHz,  $\text{CDCl}_3$ ):  $\delta$  0.88 (3H, d, 7.0, C-26 Me), 0.92 (3H, d, 7.0, C-24 Me), 0.93 (3H, t, 7.0, C-27 Me), 1.33 (1H, ddd, 12.0, 11.0, 11.0, H-18a), 1.36 (1H, m, H-27), 1.39 (1H, m, H-27), 1.43 (1H, dd, 12.0, 11.0, H-20a), 1.57 (1H, m, H-26), 1.93 (1H, dddd, 12.0, 4.5, 4.5, 2.5, H-18e), 2.12 (1H, ddd, 12.0, 4.5, 2.0, H-20e), 2.26 (1H, dqdd, 10.0, 7.5, 3.0, 2.0, H-24), 3.39 (1H, dd, 10.0, 2.0, H-25), 3.59 (1H, dd, 15.0, 9.0, H-16), 3.63 (1H, brd, 15.0, H-16), 3.80 (3H, s, OMe), 3.89 (1H, dddd, 10.0, 7.0, 4.0, 2.5, H-17), 3.94 (1H, dddd, 11.0, 11.0, 4.0, 4.0, H-19), 4.48 (2H, s,  $\text{OCH}_2\text{Ar}$ ), 5.56 (1H, dd, 10.0, 3.0, H-22), 5.74 (1H, dd, 10.0, 2.0, H-23), 6.87 (2H, d, 9.0), and 7.25 (2H, d, 9.0).

(Received in USA 4 April 1988)